ESMO 2024 | Addressing fertility concerns with new targeted cancer therapies

Isabelle Demeestere • 14 Sep 2024

ESMO 2024

General

Isabelle Demeestere, MD, PhD, Université Libre de Bruxelles (ULB), Brussels, Belgium, highlights the emerging use of targeted cancer therapies and their potential reproductive health impacts. While these drugs are generally less gonadotoxic than standard chemotherapy, there is still limited data on their long-term effects on ovarian and sperm function. Fertility counseling is essential for young patients undergoing targeted therapies, as these treatments may pose risks such as teratogenicity or pregnancy delays, making contraception discussions necessary during treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.